MAIA Biotechnology, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023; financial statements are unaudited. MAIA is a clinical-stage biotechnology company developing cancer therapies, with its lead candidate THIO being studied in advanced non-small cell lung cancer (NSCLC). The company reported no revenue.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Research and development expense | $2.60 million | $2.12 million | $4.80 million | $4.20 million |
| General and administrative expense | $2.07 million | $1.32 million | $4.05 million | $2.69 million |
| Total operating expenses | $4.66 million | $3.44 million | $8.85 million | $6.89 million |
| Net loss | $4.52 million | $3.31 million | $8.64 million | $6.72 million |
| Net loss per share, basic and diluted | $0.35 | $0.40 | $0.72 | $0.90 |
| Net cash used in operating activities | Not separately presented for the quarter | $5.92 million | $4.83 million |
At June 30, cash was $9.15 million, down from $10.95 million at December 31, 2022. Working capital was approximately $6.50 million. Current liabilities were $3.27 million; total liabilities were $3.39 million, including a $0.12 million warrant liability. The filing reports no conventional borrowing or debt balance. Net cash from financing activities was $4.12 million for the first half, primarily reflecting the April follow-on offering, partly offset by offering costs. No gross profit or operating margin is applicable because the company had no revenue.
Changes and notable items
- Compared with Q2 2022, operating expenses rose 36% and net loss increased 37%. For the first half, operating expenses rose 29% and net loss increased 29%. Higher research and development spending reflected increased scientific and preclinical activity and staffing; higher general and administrative spending reflected public-company costs, investor relations, insurance, and increased headcount.
- The April 2023 public offering issued 2,555,500 shares at $2.25 per share. The financial statements record approximately $4.40 million of net proceeds before separately reported deferred offering costs; financing cash flow was $4.12 million after those costs and related payments. Shares outstanding were 13,648,425 at June 30 and 13,625,925 as of August 8, 2023.
- Q2 included a $0.10 million gain from remeasurement of warrant liabilities. First-half Australian R&D incentive income was $0.09 million, down from $0.17 million in the prior-year period.
- The 2022 accrued employee and officer bonus was settled in May 2023 through stock options with a reported fair value of $0.97 million. The company also recognized approximately $0.49 million of consulting expense related to restricted shares issued for investor-relations services.
Outlook, risks, and contingencies
Management expects continued operating losses and negative operating cash flow as it advances clinical trials. It says additional equity or debt financing will be needed and cautions that financing may not be available on acceptable terms, or at all. The filing concludes there is substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the financial statements. No specific financial guidance or cash-runway estimate is provided.
Management reported positive topline safety lead-in results for THIO-101 Part A: THIO at the highest tested dose, in sequence with Regeneron’s cemiplimab (Libtayo), was reported as well tolerated, with no dose-limiting toxicities or significant treatment-related adverse events. The company also reported preliminary survival and disease-control observations in a small early patient group; these are preliminary clinical observations and do not establish efficacy. The trial, regulatory review, drug development, manufacturing, and need for further funding remain material risks. The Regeneron agreement provides cemiplimab for the NSCLC trial, but grants development exclusivity in NSCLC for the trial’s duration. MAIA terminated planned research activities in Russia in light of the war in Ukraine. No material legal proceedings or material changes to previously disclosed risk factors were reported.
UT Southwestern license agreements include potential milestone payments of up to $112 million per agreement, subject to specified events, and royalties on future net sales; no milestone payments were due at June 30, 2023. Management reported no material legal matters expected to adversely affect the company. The previously reported material weakness in internal control related to segregation of duties and accounting for complex transactions was reported remediated in Q2 2023 through role changes and engagement of a third-party consultant.
Important facts for investors to verify
- Reconcile reported follow-on offering proceeds: the financial statements and MD&A describe approximately $4.4 million net proceeds, while the “Use of Proceeds” section states approximately $5.1 million. Confirm the correct amount and treatment of offering costs.
- Assess funding needs, cash burn, and the going-concern warning; the filing provides no specific runway estimate.
- Track THIO-101 enrollment, safety, and efficacy as more complete data become available, distinguishing preliminary company-reported observations from established clinical benefit.
- Evaluate potential dilution from the offering, outstanding options and warrants, and the equity plan’s share-reserve provisions.